Four out of five control tumours were CD44+/CD24+ whereas all Six1-downregulated tumours lost that phenotype and were CD44−/CD24+ (Fig. 3d, e, and f and Additional file 3: Table S2). This evidence concerns the gene CD24 and neoplasm.